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Corynebacterium striatum is a nosocomial opportunistic pathogen increasingly associated with a wide 
range of human infections and is often resistant to several antibiotics. We investigated the susceptibility 
of 63 C. striatum isolated at the Farhat-Hached hospital, Sousse (Tunisia), during the period 2011–2014, 
to a panel of 16 compounds belonging to the main clinically relevant classes of antimicrobial agents. 
All strains were susceptible to vancomycin, linezolid, and daptomycin. Amikacin and gentamicin 
also showed good activity (MICs90 = 1 and 2 mg/L, respectively). High rates of resistance to penicillin 
(82.5%), clindamycin (79.4%), cefotaxime (60.3%), erythromycin (47.6%), ciprofloxacin (36.5%), 
moxifloxacin (34.9%), and rifampicin (25.4%) were observed. Fifty-nine (93.7%) out of the 63 isolates 
showed resistance to at least one compound and 31 (49.2%) were multidrug-resistant. Twenty-nine 
resistance profiles were distinguished among the 59 resistant C. striatum. Most of the strains resistant 
to fluoroquinolones showed a double mutation leading to an amino acid change in positions 87 and 91 in 
the quinolone resistance-determining region of the gyrA gene. The 52 strains resistant to penicillin were 
positive for the gene bla, encoding a class A β-lactamase. Twenty-two PFGE patterns were identified 
among the 63 C. striatum, indicating that some clones have spread within the hospital.
Corynebacterium species are widely distributed in the environment and in the microbiota of humans and ani-
mals. Medically relevant Corynebacterium species include Corynebacterium diphtheriae, the primary cause of 
diphtheria, and the non-diphtherial corynebacteria, which are part of the normal flora of the skin and mucous 
membranes. Nondiphtherial corynebacteria have been frequently dismissed as a contaminant when isolated 
from clinical materials. However, the role of these bacteria in clinical disease is now more clearly established. 
Corynebacterium striatum is recognized as a true pathogen when isolated in several samples from sterile body 
sites or from indwelling medical devices1, 2. Consideration of whether an isolate represents infection, coloniza-
tion, or contamination is based upon clinical assessment. A variety of infections have been associated with this 
bacterium: bacteremia, endocarditis, valvular damage, meningitis, vaginitis and infections of the urinary tract, 
the respiratory tract, wounds, skin and eye3–10.
Susceptibility testing of C. striatum is necessary to establish a specific therapy. Although initial studies indi-
cated that C. striatum clinical isolates were susceptible to a wide range of antibiotics11, 12, recent reports have 
shown increased multidrug resistance13, 14. Patients suffering underlying diseases and receiving multiple antibi-
otic courses are at high risk for developing serious opportunistic infections by drug-resistant C. striatum strains, 
which can be at the origin of major outbreaks. Thus, several outbreaks of clonal multidrug-resistant C. striatum 
have been recently reported15–17.
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C. striatum, considered as an emerging pathogen in different countries, has been the most frequently isolated 
Corynebacterium species since 2011 at the Farhat-Hached University (FHU) hospital, Sousse, Tunisia. In this 
study, we aimed to investigate the susceptibility of the 63 C. striatum isolated at the FHU hospital during the 
period 2011–2014 to 16 agents, representative of the main groups of antibiotics, including the most used com-
pounds to treat infections caused by Corynebacterium spp. as well as second-line and complementary agents. We 
describe the high incidence of drug resistance in our C. striatum and characterize the molecular mechanisms 
related to resistance to aminoglycosides, compounds of the MLSB group, fluoroquinolones and β-lactams. The 
clonal relationships among C. striatum isolates were analysed by Pulsed-field Gel Electrophoresis (PFGE).
Results
Antimicrobial susceptibility testing and resistance profiles. Fifty-nine (93.7%) out of the 63 isolates 
showed resistance to at least one of the 16 tested compounds, whereas the remaining 4 isolates were susceptible. 
The MIC50 and MIC90 distributions and the percentage of resistance to the different antibiotics for the 63 C. stria-
tum included in this study are presented in Table 1.
The MIC90 values of vancomycin, daptomycin and linezolid were in the range 0.25–0.5 mg/L, and none of 
the 63 isolates showed resistance against them. Considering the MIC90 values, the most active compounds were 
vancomycin and daptomycin (MIC90 = 0.25 mg/L for both compounds) followed by linezolid (MIC90 = 0.5 mg/L). 
Among the 5 aminoglycosides tested, amikacin and gentamicin were the most active compounds (MIC90 val-
ues of 1 and 2 mg/L, respectively). Only three C. striatum were resistant to both compounds (MICs > 64 mg/L). 
Tobramycin was also very active (56 isolates were susceptible). Kanamycin and streptomycin showed low activ-
ity against our C. striatum (MICs90 > 64 mg/L). The compounds of the MLSB group were poorly active against 
our C. striatum (MICs90 of 8 and >64 mg/L for erythromycin and clindamycin, respectively). Rifampicin was 
poorly active too (MIC90 = 16 mg/L). Ciprofloxacin and moxifloxacin also showed low activity against our isolates 
(MIC90 > 16 mg/L for both compounds). A high number of the isolates were resistant to the β-lactams penicillin 
and cefotaxime (MICs90 = 16 mg/L).
The 59 C. striatum resistant to at least one of the tested compounds were divided in 29 resistance pro-
files (Fig. 1). The most frequently encountered resistance phenotype was penicillin (12 strains), followed by 
penicillin-cefotaxime and erythromycin-clindamycin-penicillin (6 strains each). Multidrug resistance (MDR), 
defined as non-susceptibility to at least one agent in three or more antimicrobial categories (as defined for other 
microorganisms18), was observed in 31 (49.2%) strains. Among the 31 MDR isolates, 19 resistance profiles could 
be distinguished. Eight MDR isolates showed resistance to eight or more compounds, belonging to seven main 
classes of antibiotics (aminoglycosides, ansamycins, macrolides, lincosamides, fluoroquinolones, penicillins and 
cephalosporins).
Molecular detection of resistance genes. The aph(3′)-Ic gene was detected in the 10 strains resistant to 
kanamycin (MIC > 64 mg/L). However, fourteen strains susceptible to kanamycin were also aph(3′)-Ic-positive. 
The genes aph(3″)-Ib and aph(6)-Id were detected in 8 isolates, five of them resistant to streptomycin 
(MICs > 64 mg/L), and the other three showed MICs of streptomycin in the range 1–4 mg/L. The gene aac(3)-XI 
was found in 7 isolates. Two of them were susceptible to both gentamicin and tobramycin (MICs < 0,06 mg/L) 
whereas the other five isolates showed MICs of 8 and 16 mg/L for gentamicin and tobramycin, respectively.
Antimicrobial agent Range (mg/L) MIC50 MIC90
Breakpoint
Resistant Intermediate Total (%) RS I R
Amikacin 0.06–64 0.06 1 ≤16 32 ≥64 3 0 3 (4.8%)
Gentamicin 0.06–64 0.06 2 ≤4 8 ≥16 3 1 4 (6.3%)
Kanamicin 0.016–256 0.125 >64 ≤16 32 ≥64 10 1 11 (17.5%)
Tobramicin 0.06–64 0.06 8 ≤4 8 ≥16 3 4 7 (11.1%)
Streptomycin 0.125–64 2 >64 ≤8 >16 8 2 10 (15.9%)
Erythromycin 0.06–64 0.5 8 ≤0.5 1 ≥2 24 6 30 (47.6%)
Clindamycin 0.06–64 1 >64 ≤0.5 2 ≥4 24 26 50 (79.4%)
Doxycicline 0.06–16 0.06 8 ≤4 8 ≥16 0 11 11 (17.5%)
Ciprofloxacin 0.015–16 0.125 >16 ≤1 2 ≥4 21 2 23 (36.5%)
Moxifloxacin 0.06–16 0.06 >16 ≤0.5 1 ≥2 15 7 22 (34.9%)
Penicillin 0.06–64 1 16 ≤0.125 52 0 52 (82.5%)
Cefotaxime 0.25–256 2 16 ≤1 2 ≥4 28 10 38 (60.3%)
Rifampicin 0.015–64 0.015 16 ≤1 2 ≥4 14 2 16 (25.4%)
Vancomycin 0.06–1 0.25 0.25 ≤2 0 0 0
Linezolid 0.015–1 0.25 0.5 ≤4 ≥8 0 0 0
Daptomycin 0.015–1 0.125 0.25 ≤1 0 0 0
Table 1. Susceptibility of 63 Corynebacterium striatum clinical isolates to 16 antimicrobial agents. Isolates were 
classified as resistant, intermediate, or susceptible, according to criteria defined by CLSI38. MIC, minimum 
inhibitory concentration; MIC50/90, MIC that inhibits 50% and 90% of the isolates, respectively.
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Twenty out of the 24 C. striatum resistant to erythromycin carried the erm(X) gene. Ten out of 20 carried 
erm(X) plus the erm(B) gene. From the 24 clindamycin-resistant isolates 22 were positive for the gene erm(X) and 
10 out of 22 were also erm(B)-positive. The mef(A-E) gene was not found in any strain tested.
The sequences of the QRDR region of the gyrA gene of 21 isolates categorized as resistant or intermediate to 
fluoroquinolones were compared to that of the quinolone-susceptible C. striatum ATCC 6940 (GenBank acces-
sion number AY559038). The relationships between the MICs of ciprofloxacin and moxifloxacin and the muta-
tions in the gyrA QRDRs of the 21 isolates are summarized in Table 2. Eleven strains showing MICs = 16 mg/L 
for these two compounds carried a double mutation at resistance hotspots Ser-87 and Asp-91 (C. striatum num-
bering), generating a change from Ser-87 to Phe and another change from Asp-91 to Gly or Ala. In two double 
Figure 1. PFGE patterns and antibiotic resistance profiles of the 63 C. striatum. An: amikacin; Gm: gentamicin; 
Km: kanamycin; Sm: streptomycin; Tob: tobramycin; Rif: rifampicin; Eri: erythromycin; Clin: clindamycin; Cip: 
ciprofloxacin; Mox: moxifloxacin; Pen: penicillin; Ctx: cefotaxime.
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mutants showing the same changes the increase of MICs of moxifloxacin was limited to 8 mg/L. Another double 
mutant with Ala instead of Ser in position 87 and Gly instead of Asp in position 91 showed lower MIC of mox-
ifloxacin (4 mg/L) whereas the MIC of ciprofloxacin was >16 mg/L. Three strains had a mutation at amino acid 
codon Ser-87 that changes this amino acid for Tyr or Phe. These single mutants showed lower increases of MICs 
of ciprofloxacin (to 4 or 8 mg/L) and a moderate increase of MICs of moxifloxacin (to 1 mg/L). Two strains 
showed a replacement in the amino acid codon Asp-91, producing a change from Asp to Gly. The MICs of cipro-
floxacin and moxifloxacin for these strains were 2 and 1 mg/L, respectively. Two fluoroquinolone-resistant isolates 
lacked mutations in their QRDRs.
The 52 isolates showing resistance to penicillin were positive for the gene bla, encoding a class A β-lactamase. 
The C. striatum bla gene encodes a serine hydrolase belonging to the class A β-lactamase family protein. Forty-six 
out of the 63 C. striatum were positive for the ampC gene, encoding a class C β-lactamase. Forty-two of the 46 
ampC-positive isolates were penicillin-resistant whereas 4 isolates were sensitive. The ampC gene was detected in 
22 of the 28 cefotaxime-resistant C. striatum. The 52 penicillin-resistant isolates had MICs of cefotaxime in the 
range 1–256 mg/L.
Analysis of the strain clonal relationship by PFGE. XbaI digestion of the 63 C. striatum isolates 
revealed 22 distinct PFGE patterns, which were designated from A to V (Fig. 1). On these, PFGE types D and G 
could be further classified into 3 subtypes. Pulsotype E was predominant (n = 12 isolates) and it was observed 
in 11 MDR strains, six of which were isolated in the neonatology ward. The remaining 20 MDR clinical isolates 
belonged to PFGE patterns A (n = 6), C, D2, G3 (n = 2), H, J, K, N, O (n = 2), P, Q (n = 2) and S, indicating that 
they were unrelated. Other patterns including a significant number of isolates were A (n = 7), D (n = 7) and G 
(n = 9). Relationship between PFGE patterns and antibiotic resistance profiles could not be established, although 
the most prevalent PFGE patterns (E and A) included principally MDR isolates. Two pairs of isolates assigned to 
pulsotype E showed the same resistance profile.
Discussion
One of the most serious problems related to treatment of the infections caused by C. striatum is the isolation of 
multidrug-resistant strains from clinical material and the selection of the appropriate antibiotic therapy for a 
given type of infection. C. striatum infections should be treated according to the results of the susceptibility tests. 
Multiple drug resistance is caused by the interplay of multiple resistance mechanisms those emerge via the acqui-
sition of extraneous resistance determinants or spontaneous mutations. This work highlights the high prevalence 
of multi-resistant strains and resistance genes among the C. striatum isolated in a hospital in Tunisia, in particular 
resistance to aminoglycosides, compounds of the MLSB group, fluoroquinolones, and β-lactams.
The 63 C. striatum analysed in this study were susceptible to vancomycin and linezolid. In an earlier report 
using the disk diffusion method, Martinez et al.19 showed that 31 C. striatum isolated from clinical samples 
were susceptible to vancomycin. More recently, Gomila et al.20 reported that their 52 C. striatum isolated from 
patients with chronic obstructive respiratory disease were susceptible to vancomycin too. Vancomycin is still 
active today and therefore it represents an adequate option for treatment of severe infections caused by C. stria-
tum. Linezolid has also shown an excellent activity, with MICs routinely below 0.5 mg/L21. Gómez-Garcés et al.22 
showed that vancomycin and linezolid were equally active against 30 clinical C. striatum (MICs90 of both com-
pounds = 0.5 mg/L). Linezolid can be considered as an alternative to vancomycin against C. striatum, although 
its side effects during the long courses of treatment required for hardware or device-associated infections must 
be pondered. All our C. striatum were susceptible to daptomycin (MIC90 = 0.25 mg/L). Daptomycin has also been 
proven to be active against C. striatum, alone23 or combined with rifampicin24. Therefore, daptomycin can also be 
considered as an alternative to vancomycin for treatment of C. striatum infections, although rapid emergence of 
high-level daptomycin resistance has been recently reported25, 26.
Aminoglycosides are used as complementary antibiotics to treat serious infections caused by diphtheroids. 
Among aminoglycosides, amikacin and gentamicin showed good activity “in vitro” against our C. striatum 
(MICs90 = 1 and 2 mg/L, respectively). Aminoglycoside resistance occurs through several mechanisms that can 
coexist simultaneously in the same cell. Enzymatic inactivation of the antibiotic molecule is the most prevalent in 
Number of 
strains
Ciprofloxacin Moxifloxacin
MIC (mg/L) Phenotype MIC (mg/L) Phenotype Ser-87 Asp-91
8 >16 R >16 R Phe Gly
3 >16 R >16 R Phe Ala
1 >16 R 8 R Phe Gly
1 >16 R 8 R Phe Ala
1 >16 R 4 R Ala Gly
1 8 R 1 I Phe Asp
2 4 R 1 I Tyr Asp
2 2 I 1 I Ser Gly
1 8 R 1 I Ser Asp
1 4 R 1 I Ser Asp
Table 2. Relationship between mutations in the QRDR regions of the gyrA gene and the MICs for 21 C. 
striatum classified as resistant or intermediate to fluoroquinolones.
www.nature.com/scientificreports/
5Scientific RepORTS | 7: 9704  | DOI:10.1038/s41598-017-10081-y
the clinical setting. The aac(3)-XI gene, encoding an aminoglycoside 3-N acetyl transferase conferring resistance 
to gentamicin and tobramycin in C. striatum27, was not found in our 3 gentamicin-resistant isolates, suggesting 
that resistance is mediated by another mechanism. Kanamycin and streptomycin are not used in clinical practice 
in Tunisia but were tested in this study because they are good markers for detecting the presence of the aph(3′)-Ic, 
aph(3″)-Ib and aph(6)-Id genes. The aph(3′)-Ic gene, encoding an aminoglycoside-O-phosphotransferase impli-
cated in resistance to kanamycin, neomycin, paromomycin, ribostamycin and lividomycin, is part of a larger 
DNA region containing the aph(3″)-Ib - aph(6)-Id tandem pair of resistance genes conferring streptomycin resist-
ance in Corynebacterium spp28. Identical aminoglycoside resistance regions were found in the plasmid pTP10 
from C. striatum in close vicinity to the erythromycin and chloramphenicol resistance regions29. As expected, 
the 10 C. striatum resistant to kanamycin carried the aph(3′)-Ic gene. However, this gene was also detected in 
strains susceptible to kanamycin, probably due to mutations affecting its coding sequence or its promoter. These 
results confirm that the aph(3′)-Ic gene is widespread in Corynebacterium spp. Resistance to streptomycin in 
Corynebacterium spp. is related to the presence of the tandem of genes aph(3″)-Ib and aph(6)-Id, encoding for 
aminoglycoside-3″-phosphotransferase [APH (3″)-Ib] and aminoglycoside-6-phosphotransferase [APH (6)-Id], 
respectively28. Five of the 8 isolates resistant to streptomycin carried the aph(3″)-Ib and aph(6)-Id genes, and the 
remaining three had MICs for streptomycin in the range of 1 to 4 mg/L, probably as a consequence of mutations 
in the above mentioned genes or in their promoter. Other mechanisms such as active efflux of the antimicrobial 
and reduced intake into the bacterial cell can contribute to streptomycin resistance in these isolates. Amikacin 
is eventually prescribed in combinative therapy against severe infections caused by C. striatum at the FHU hos-
pital. Our results indicate that amikacin is the preferable aminoglycoside for treatment of C. striatum infections 
whereas gentamicin could be a valid alternative. However, the occurrence of resistant strains requires continual 
vigilance.
Erythromycin and clindamycin were inactive against the majority of our C. striatum, in particular clindamy-
cin, with a MIC90 eight times greater than that of erythromycin. This fact confirms the previously reported high 
prevalence of resistance to compounds of the MLSB group among Corynebacterium spp., including C. striatum30. 
MLS resistance in Corynebacterium spp. is most often mediated by two mechanisms: target-site modification 
mediated by ribosomal RNA methylases codified by the so-called erm genes and active drug-efflux mediated by 
a membrane efflux pump encoded by the mef(A-E) gene31. Our results confirmed those of previous studies which 
pointed out that erm(X) is the most important gene implicated in MLS resistance in Corynebacterium spp29, 32. For 
the first time we have detected the erm(B) gene encoding the ribosomal RNA methylase Erm(B) in C. striatum. 
The gene erm(B) confers high-level resistance to macrolides in Campylobacter coli33 and other relevant pathogens 
but is exceptional in Corynebacterium spp31, 34. Ten of our strains carried the erm(B) and erm(X) genes simultane-
ously, a characteristic previously reported only in one strain of C. urealyticum31.
One third of our C. striatum showed intermediate or high-level resistance to ciprofloxacin and moxifloxacin. 
Fluoroquinolones have been intensively used at the FHU hospital during the last two decades. Upon antibi-
otic administration, a selective pressure is created in body organs where fluoroquinolones tend to accumulate. 
Exposure to fluoroquinolones selects for spontaneous mutants in large bacterial populations, including those 
that colonize the skin and mucous membranes such as corynebacteria. Thus, fluoroquinolone resistance emerged 
in clinical isolates of C. striatum and C. amycolatum35. Resistance to fluoroquinolones in Corynebacterium spp. 
is caused by mutations in the QRDR of the gyrase gene gyrA. In our strains, single amino-acid substitutions in 
position 87 of the GyrA protein generated ciprofloxacin resistance but double mutations in the gyrA gene leading 
to changes in positions 87 and 91 were necessary for high level resistance to ciprofloxacin and moxifloxacin. In 
fourteen of the 21 fluoroquinolone-resistant C. striatum, increases of MICs of ciprofloxacin and moxifloxacin 
until 16 mg/L were related to a double non-conservative mutation at positions 87 and 91. Sierra et al.35 also 
reported double mutations at positions 87 and 91 in the gyrA gene of six of their C. striatum, although the MICs 
of moxifloxacin for their strains were lower (6–8 mg/L). Five of our strains with single mutations at positions 87 
or 91 are still resistant to ciprofloxacin although with lower MICs (in the range 2–8 mg/L) whereas the MICs of 
moxifloxacin remained at 1 mg/L. Single mutations in the residue Ser-87 or in the residue Asp-91 described by 
Sierra et al.35 increased the MICs of ciprofloxacin to 1–6 mg/L, whereas remaining susceptible to moxifloxacin. 
The higher level of moxifloxacin resistance in our strains suggest the existence of a resistance mechanism addi-
tional to mutations in gyrA. In two strains no changes in their QRDRs were detected, indicating that resistance 
was mediated by a different mechanism.
β-lactams are the most broadly used class of antimicrobials. Successful treatments of C. striatum infections 
with penicillin36 or amoxicillin37 have been reported. However, low susceptibility to penicillin and cefotaxime 
among other β-lactams have been communicated10, 38, although the genetic mechanism of resistance has not 
been characterized so far. Considering the MICs90 values (16 mg/L), penicillin and cefotaxime showed the same 
low activity against our C. striatum. The fact that the rate of penicillin-resistant strains is higher than that of 
cefotaxime-resistant strains is explained because the CLSI susceptibility breakpoint for penicillin has recently 
been dropped from 1 mg/l to 0.125 mg/L39. Hydrolysis of β-lactam antibiotics by β-lactamases is the most common 
mechanism of resistance for this class of antibacterial agents in clinically important bacteria. The β-lactamases 
are classified by protein sequence in four molecular classes, A, B, C, and D, based on conserved and distinguish-
ing amino acid motifs. Fifty-two of our strains were resistant to penicillin and this resistance was related to the 
presence of a bla gene encoding a class A β-lactamase. The chromosomes of Corynebacterium jeikeium K41140, 
Corynebacterium urealyticum DSM 710941, and Corynebacterium resistens DSM 4510042, encode the correspond-
ing counterparts of the C. striatum bla gene, although it has not been associated with resistance to β-lactams in 
these species. The ampC gene, encoding a class C β-lactamase, was detected in 42 of the 52 penicillin-resistant C. 
striatum. The ampC genes, which are widely distributed among the Enterobacteriaceae, encode enzymes active 
on both penicillins and cephalosporins43. We show here that two β-lactamase-encoding genes, bla and ampC, 
are present in β-lactam-resistant C. striatum. Our data revealed high resistance rates to β-lactams and a high 
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prevalence of the bla and the ampC genes among the C. striatum isolated in our hospital. These data are of value to 
practitioners, discouraging the use of β-lactam compounds for the treatment of infections caused by C. striatum.
PFGE is considered the gold standard in epidemiological studies of pathogenic microorganisms, providing 
important insights into their population structure44. Our results showed 22 distinct PFGE patterns from 63 C. 
striatum strains. The high diversity of genotypes among the 63 C. striatum revealed that they are mainly not 
closely related. Therefore, C. striatum at the FHU hospital may originate from different lineages and sources 
instead of expansion of a single clonal lineage. This corresponds to the pathogenic condition of C. striatum as an 
opportunistic pathogen that causes occasional disease in predisposed patients. Some PFGE patterns were more 
frequently isolated, suggesting the existence of a few more prevalent clones. We consider patterns E and A as 
high-prevalence pulsotypes. Most of C. striatum assigned to pulsotypes E and A were highly resistant, indicating 
that the most prevalent clones are highly resistant, as has been previously reported10, 16. The fact that many differ-
ent antibiotic resistance profiles could be distinguished among the strains belonging to a particular PFGE pattern 
revealed that there was not a single strain but several closely related clones producing sporadic infections.
In conclusion, this study highlights the relevance of C. striatum as an emerging multidrug-resistant nosoco-
mial pathogen at the FHU hospital. The C. striatum isolates showed 100% susceptibility to vancomycin, linezolid 
and daptomycin and high rates of resistance to rifampicin, compounds of the MLSB group, fluoroquinolones and 
β-lactams. Among the several clones of C. striatum circulating at the FHU hospital, the most prevalent were the 
most resistant. Therefore, surveillance of MDR C. striatum should be continued.
Methods
Bacterial strains and growth conditions. During the period 2011–2014, 90 strains recovered from clin-
ical specimens submitted for routine culture to the microbiology laboratory of the FHU hospital were assigned 
to the genus Corynebacterium on the basis of colony morphology, Gram staining, and catalase production. They 
were isolated in pure culture except the 7 specimens from vaginal swabs, where the Corynebacterium were the 
predominant microorganisms in a poly-microbial culture. In that cases the Corynebacterium were considered of 
clinical significance since they were associated with a strong leukocyte reaction in Gram staining45. In all cases the 
Corynebacterium were isolated after two different culture sets. Sixty-three out of the 90 strains were identified as 
putative C. striatum using API Coryne V2.0 strips (bioMérieux, Marcy l’Etoile, France). C. striatum was differen-
tiated from C. amycolatum by additional phenotypic tests (tyrosine hydrolysis, N-acetylglucosamine assimilation, 
phenylacetic acid assimilation and susceptibility to the vibriostatic agent O/129). Identification was confirmed by 
MALDI-TOF using the Vitek MS (bioMérieux) system, in accordance with manufacturer’s instructions. The ana-
tomical sites of specimens from whom the 63 C. striatum were isolated and the clinical diagnosis for the infected 
patients are shown in Table 3. All strains were grown on blood agar plates at 37 °C and kept frozen at −80 °C in 
Brain Heart Infusion broth with 20% glycerol until use.
Antimicrobial susceptibility assays. Antimicrobial susceptibilities were determined by micro-dilution 
in cation adjusted Muller-Hinton broth and interpreted following Clinical and Laboratory Standards Institute 
(CLSI) guidelines39. Sixteen antimicrobials were tested: amikacin, gentamicin, kanamycin, streptomycin, tobra-
mycin, rifampicin, erythromycin, clindamycin, doxycycline, ciprofloxacin, penicillin, cefotaxime, vancomycin 
(all of them purchased from Sigma Aldrich, Madrid, Spain), moxifloxacin (Discovery Fine Chemicals, Dorset, 
United Kingdom), linezolid (Pfizer, Bilbao, Spain) and daptomycin (Cubist, Madrid, Spain). Daptomycin broth 
was supplemented to 50 mg/L calcium for determinations of susceptibility to that drug. Of note, CLSI suscep-
tible interpretive criteria for penicillin has been recently dropped from 1 mg/l to 0.125 mg/L39. MIC values of 
the antibiotics not considered in CLSI guidelines for Corynebacterium spp. (amikacin, tobramycin, kanamy-
cin, moxifloxacin and linezolid) were interpreted in accordance to criteria defined by CLSI for Staphylococcus 
aureus46. Since the CLSI lacks breakpoints of streptomycin for staphylococci we have considered the MIC break-
points values proposed by the French Society of Microbiology (http://www.sfmmicrobiologie.org/UserFiles/files/
casfm/CASFM2013vjuin.pdf) to classify the C. striatum as susceptible, intermediate or resistant to streptomycin. 
Anatomical site N° isolates Diagnosis
Wound 23 Surgical site infection; cellulitis
Vaginal swabs 7 Leucorrhoea
Ear effusion 9 Otitis
Urine 6 Urinary infection; urinary tract catheter colonization
Sputa 5
Chronic obstructive 
pulmonary disease; 
pneumonia
Tracheal aspirates 4 Tracheobronchitis
Eyes effusion 3 Congenital infection
CVC tips 3 CVC-exit site colonization
Blood 1 Septicemia
IU Device 1 IU device colonization
Sperm 1 Sterility
Table 3. Sources of specimens from whom C. striatum were isolated and clinical diagnosis for the 63 infected 
patients. CVC: Central Venous Catheter; IU: Intrauterine.
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Escherichia coli ATCC 25922 and Streptococcus pneumoniae ATCC49619 were used as control strains for suscep-
tibility testing assays.
Amplification and sequencing of genes related to resistance. The presence of aminoglycoside mod-
ifying enzyme (AME) genes common in Corynebacterium spp. [aph(3′)-Ic, aac(3)-XI, and the tandem of genes 
aph(3″)-Ib and aph(6)-Id] was investigated by PCR. Resistance to compounds of the MLSB group was investigated 
by amplification of the erm(X), erm(B) and mef(A-E) genes. Resistance to quinolones in Corynebacterium spp. is 
related to point mutations in the sequence of the quinolone resistance-determining region (QRDR) of the gyrA 
gene. Thereby, the QRDR at that gene was amplified and sequenced as previously described35. The 63 C. striatum 
were analysed for the presence of the bla gene, encoding a class A β-lactamase involved in resistance to penicillins 
and cephalosporins in Corynebacterium spp. Primers used to amplify the above mentioned genes are listed in 
Supplementary Table S1. PCR reactions were performed as previously described47. PCR products were purified 
using the QIAquick PCR Purification kit (Qiagen, Madrid, Spain). Purified DNA was sequenced by Macrogen 
(Seul, Korea) with the primers outlined in Table S1. Mutations in gyrA were identified by aligning sequences of 
resistant isolates to the sequence of C. striatum ATCC6940 (GenBank accession number AY559038) using the 
Clustal W program47.
Pulsed-field Gel Electrophoresis and dendrogram analysis. We obtained XbaI macro-restriction 
patterns of the 63 C. striatum with a published protocol48 and a CHEF-DRIII variable angle system (Bio-Rad, 
Hercules, California, USA). The PFGE patterns were analysed with Fingerprinting II v4.5 software (Bio-Rad). 
Each isolate was compared with all other isolates using the Dice similarity coefficient and the unweighted pair 
Group method with arithmetic means (UPGMA), with 1% of optimization and tolerance. Isolates were classified 
as indistinguishable if they showed 100% similarity, as closely related subtypes if they showed 95–99% similarity, 
and as different strains if they showed <95% similarity.
Ethics statement. This study was performed in accordance with the ethical guidelines of the Declaration 
of Helsinki (1975). Written informed consent was obtained from each patient from whom samples were taken.
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